Down-regulation of mitogen-activated protein kinases and nuclear factor-κB signaling is involved in rapamycin suppression of TLR2-induced inflammatory response in monocytic THP-1 cells

Microbiology and Immunology

Volumn 59, Issue 10, 2015, Pages 614-622

  Sun, Ruili ^a,b   Zhang, Yi ^a   Ma, Shijiang ^a   Qi, Hengtian ^a   Wang, Mingyong ^a   Duan, Juhong ^a   Ma, Shujun ^a   Zhu, Xiaofei ^a   Li, Guancheng ^b   Wang, Hui ^a  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

MAPKs; Nuclear factor B; Rapamycin; Toll like receptor 2

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN PAM3CSK4; RAPAMYCIN; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT; LIPOPEPTIDE; PAM(3)CSK(4) PEPTIDE; TLR2 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MONOCYTE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL LINE; DOWN REGULATION; DRUG EFFECTS; GENETICS; INFLAMMATION; METABOLISM;

CELL LINE; CYTOKINES; DOWN-REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LIPOPEPTIDES; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIROLIMUS; TOLL-LIKE RECEPTOR 2;

EID: 84944452796     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/1348-0421.12321     Document Type: Article

References (38)

1. Medzhitov R., Preston-Hurlburt P., Janeway C.A. Jr. (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-7.
2. Hashimoto C., Hudson K.L., Anderson K.V. (1988) The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 52: 269-79.
3. Baccala R., Gonzalez-Quintial R., Lawson B.R., Stern M.E., Kono D.H., Beutler B., Theofilopoulos A.N. (2009) Sensors of the innate immune system: their mode of action. Nat Rev Rheumatol 5: 448-56.
4. Anders H.J., Schlondorff D.O. (2010) Innate immune receptors and autophagy: implications for autoimmune kidney injury. Kidney Int 78: 29-37.
5. Takeda K., Kaisho T., Akira S. (2003) Toll-like receptors. Annu Rev Immunol 21: 335-76.
6. Vezina C., Kudelski A., Sehgal S.N. (1975) Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 28: 721-6.
7. Groth C.G., Bäckman L., Morales J.M., Calne R., Kreis H., Lang P., Touraine J.L., Claesson K., Campistol J.M., Durand D., Wramner L., Brattström C., Charpentier B. (1999) Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67: 1036-42.
8. Fernandez D., Bonilla E., Mirza N., Niland B., Perl A. (2006) Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 54: 2983-8.
9. Fantus D., Thomson A.W. (2015) Evolving perspectives of mTOR complexes in immunity and transplantation. Am J Transplant 15: 891-902.
10. Menon S., Manning B.D. (2008). Common corruption of the mTOR signaling network in human tumors. Oncogene 27 (Suppl 2): S43-S51.
11. Yecies J.L., Manning B.D. (2011) Transcriptional control of cellularmetabolism by mTOR signaling. Cancer Res 71: 2815-20.
12. Csibi A., Fendt S.M., Li C., Poulogiannis G., Choo A.Y., Chapski D.J., Jeong S.M., Dempsey J.M., Parkhitko A., Morrison T., Henske E.P., Haigis M.C., Cantley L.C., Stephanopoulos G., Yu J., Blenis J. (2013) The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SI RT4. Cell 153: 840-54.
13. Laplante M., Sabatini D.M. (2012) mTOR signaling in growth control and disease. Cell 149: 274-93.
14. Krebs M., Brunmair B., Brehm A., Artwohl M., Szendroedi J., Nowotny P., Roth E., Fürnsinn C., Promintzer M., Anderwald C., Bischof M., Roden M. (2007) The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes 56: 1600-7.
15. Tremblay F., Marette A. (2001) Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 276: 38052-60.
16. Muncy J., Butler I.J., Koenig M.K. (2009) Rapamycin reduces seizure frequency in tuberous sclerosis complex. J Child Neurol 24: 477.
17. Sato A., Kasai S., Kobayashi T., Takamatsu Y., Hino O., Ikeda K., Mizuguchi M. (2012) Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex. Nat Commun 3: 1292.
18. McCormack F.X., Inoue Y., Moss J., Singer L.G., Strange C., Nakata K., Barker A.F., Chapman J.T., Brantly M.L., Stocks J.M., Brown K.K., Lynch J.P. 3rd, Goldberg H.J., Young L.R., Kinder B.W., Downey G.P., Sullivan E.J., Colby T.V., McKay R.T., Cohen M.M., Korbee L., Taveira-DaSilva A.M., Lee H.S., Krischer J.P., Trapnell B.C. (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364: 1595-606.
19. Bove J., Martinez-Vicente M., Vila M. (2011) Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci 12: 437-52.
20. Johnson S.C., Yanos M.E., Kayser E.B., Quintana A., Sangesland M., Castanza A., Uhde L., Hui J., Wall V.Z., Gagnidze A., Oh K., Wasko B.M., Ramos F.J., Palmiter R.D., Rabinovitch P.S., Morgan P.G., Sedensky M.M., Kaeberlein M. (2013) mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science 342: 1524-8.
21. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., Nadon N.L., Wilkinson J.E., Frenkel K., Carter C.S., Pahor M., Javors M.A., Fernandez E., Miller R.A. (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460: 392-5.
22. Lamming D.W., Ye L., Sabatini D.M., Baur J.A. (2013) Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest 123: 980-9.
23. Dienstmann R., Rodon J., Serra V., Tabernero J. (2014) Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther 13: 1021-31.
24. Kawasaki T., Kawai T. (2014) Toll-like receptor signaling pathways. Front Immunol 5: 461.
25. Medvedev A.E., Kopydlowski K.M., Vogel S.N. (2000) Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression. J Immunol 164: 5564-74.
26. Huang J., Manning B.D. (2009) A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 37: 217-22.
27. Ehninger D. (2013) From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches. Neuropharmacology 68: 97-105.
28. Klann E., Dever T.E. (2004) Biochemical mechanisms for translational regulation in synaptic plasticity. Nat Rev Neurosci 5: 931-42.
29. Costa-Mattioli M., Sonenberg N., Richter J.D. (2009) Translational regulatory mechanisms in synaptic plasticity and memory storage. Prog Mol Biol Transl Sci 90: 293-311.
30. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648-57.
31. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C. (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide3-kinase/akt pathway. Mol Cell 10: 151-62.
32. Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., Cichowski K. (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 102: 8573-8.
33. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., Pandolfi P.P. (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121: 179-93.
34. Inoki K., Zhu T., Guan K.L. (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-90.
35. Fukao T., Tanabe M., Terauchi Y., Ota T., Matsuda S., Asano T., Kadowaki T., Takeuchi T., Koyasu S. (2012) PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat Immunol 3: 875-81.
36. Martin M., Rehani K., Jope R.S., Michalek S.M. (2005) Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6: 777-84.
37. Liu H.E., Chang A.S., Teng C.M., Chen C.C., Tsai A.C., Yang C.R. (2011) Potent anti-inflammatory effects of denbinobin mediated by dual inhibition of expression of inducible NO synthase and cyclooxygenase 2. Shock 35: 191-7.
38. Lorne E., Zhao X., Zmijewski W.J., Liu G., Park Y.-J., Tsuruta Y., Abraham E. (2009) Participation of mammalian target of Rapamycin complex 1 in toll-like receptor 2- and 4-induced neutrophil activation and acute lung injury. Am J Respir Cell Mol Biol 41: 237-45.